Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 220-099-6 | CAS number: 2627-95-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 05 August 2019 to 21 January 2020
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 020
- Report date:
- 2020
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.3700 (Prenatal Developmental Toxicity Study)
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- 1,1,3,3-tetramethyl-1,3-divinyldisiloxane
- EC Number:
- 220-099-6
- EC Name:
- 1,1,3,3-tetramethyl-1,3-divinyldisiloxane
- Cas Number:
- 2627-95-4
- Molecular formula:
- C8H18OSi2
- IUPAC Name:
- ethenyl[(ethenyldimethylsilyl)oxy]dimethylsilane
Constituent 1
- Specific details on test material used for the study:
- STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: controlled temperature area set to maintain 18°C to 24°C, in a flame-proof cabinet, capped with nitrogen
- Stability under test conditions: Stable
- Solubility and stability of the test substance in the solvent/vehicle: Test substance formulations have been previously shown to be stable and homogenous over the range of concentrations used in in this study for at least 10 days when stored in a refrigerator set to maintain a target of 5°C.
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: The vehicle, corn oil, was dispensed approximately weekly for administration to Group 1 control animals and preparation of the test substance formulations, which were stored at room temperature (18°C to 24°C), protected from light, until use. The vehicle was stirred continuously during dosing. Test substance dosing formulations were prepared at appropriate concentrations to meet dose level requirements.
- Preliminary purification step (if any): none
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Remarks:
- Crl:CD
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Inc., Raleigh, NC
- Age at study initiation: 11–13 weeks old
- Weight at study initiation: 200 and 250 g on Gestation Day 0
- Fasting period before study:
- Housing: Animals were individually housed in solid-bottom cages containing appropriate bedding equipped with an automatic watering valve
- Diet (e.g. ad libitum): PMI Nutrition International, LLC Certified Rodent LabDiet® 5002 meal was provided ad libitum
- Water (e.g. ad libitum): Municipal tap water after treatment by reverse osmosis and ultraviolet irradiation was freely available to each animal via an automatic watering system
- Acclimation period: yes
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20°C to 26°C
- Humidity (%): 30% to 70%
- Air changes (per hr): Ten or greater air changes per hour with 100% fresh air.
- Photoperiod (hrs dark / hrs light): 12-hour light/12-hour dark cycle
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: Test substance dosing formulations were prepared at appropriate concentrations to meet dose level requirements. The dosing formulations were prepared approximately weekly and an adequate amount of each formulation was dispensed into daily aliquots, which were stored refrigerated (target of 5°C), protected from light, until use.
VEHICLE
- Justification for use and choice of vehicle (if other than water): Corn oil was chosen as the appropriate vehicle based on the test substance’s characteristics and
the subsequent relevant OECD testing guidelines.
- Concentration in vehicle: 0, 12.5, 37.5, 150 mg/mL
- Amount of vehicle (if gavage): not specified
- Lot/batch no. (if required): 2IC0148 and 1IG1538
- Purity: not specified - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Dose formulation samples were collected for analysis twice during the study period. Concentration analysis was performed on duplicate sets of all dose levels. Concentration results were considered acceptable if mean sample concentration results were within or equal to ± 15% of theoretical concentration. Homogeneity analysis of the dose formulations was performed once during the study on duplicate sets of low and high dose groups. Homogeneity results were considered acceptable if the relative standard deviation of the mean value at each sampling location was ≤ 10% and if mean sample concentration results were within or equal to ± 15% of theoretical concentration. Stability was not assessed as the test substance formulations have been previously shown to be stable and homogenous over the range of concentrations used in in this study for at least 10 days when stored in a refrigerator set to maintain a target of 5°C.
- Details on mating procedure:
- The females were time-mated and were received on Gestation Day 1, 2, 3, or 4.
- Duration of treatment / exposure:
- From gestation day 6 to gestation day (GD) 20.
- Frequency of treatment:
- daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day (actual dose received)
- Remarks:
- control group
- Dose / conc.:
- 50 mg/kg bw/day (actual dose received)
- Remarks:
- low dose group
- Dose / conc.:
- 150 mg/kg bw/day (actual dose received)
- Remarks:
- medium dose group
- Dose / conc.:
- 600 mg/kg bw/day (actual dose received)
- Remarks:
- high dose group
- No. of animals per sex per dose:
- 25 females per group
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: The target exposure concentrations were selected based on a previous 14-day repeated-dose study and an OECD 422 combined repeated dose toxicity study with the reproduction/developmental toxicity screening test.
- Rationale for animal assignment (if not random): random
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily
- Cage side observations checked for mortality and moribundity.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: once daily
BODY WEIGHT: Yes
- Time schedule for examinations: Animals were weighed individually on Gestation Days 0 (by supplier) and 5–21 (daily).
FOOD CONSUMPTION: Yes
- Time schedule for examinations: Food consumption was quantitatively measured on Gestation Days 5–21 (daily)
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day # 21
- Organs examined: Animals were subjected to a complete necropsy examination, which included evaluation of the thoracic, abdominal, and pelvic cavities with their associated organs and tissues as well as the thyroid gland. Furthermore, kidney, liver and thyroid gland were weighed at necropsy. The thyroid gland was examined hystopathologically.
OTHER:
THYROID HORMONES EXAMINATIONS: Yes
- Time schedule for examinations: Blood samples for thyroid hormone analyses (triiodothyronine (Total T3); thyroxine (Total T4); thyroid-stimulating hormone (TSH)) were collected (prior to noon in order to avoid diurnal fluctuations in thyroid hormone levels) from a jugular vein into tubes without anticoagulants on GD 21 from all animals. - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
- Other:
- Live and dead fetuses: Yes
- Placeta examination: Yes - Fetal examinations:
- - External examinations: Yes: [all per litter ]
- Soft tissue examinations: Yes: [half per litter]
- Skeletal examinations: Yes: [half per litter ]
- Head examinations: No - Statistics:
- Levene’s test11 was used to assess the homogeneity of group variances. The groups were compared using an overall one-way ANOVA F-test if Levene’s test was not significant or the Kruskal-Wallis test if it was significant. If the overall F-test or Kruskal-Wallis test was found to be significant, then pairwise comparisons were conducted using Dunnett’s or Dunn’s test, respectively.
The groups were compared using an overall Kruskal-Wallis test. If the overall Kruskal-Wallis test was found to be significant, then the above pairwise comparison was conducted using Dunn’s test.
A Fisher’s Exact Test16 was used to conduct pairwise group comparisons of interest. - Indices:
- Pre-implantation loss, post-implantation loss, sex ratio, litter % of fetuses with abnormalities
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- No test substance-related clinical observations were noted at the daily examinations or approximately 1 hour following dose administration at any dosage level.
Observations noted in the test substance-treated groups, primarily including thin fur cover and scabbing on various body surfaces, occurred infrequently, at similar frequencies in the control group, and/or in a manner that was not dose-related.
All females were gravid, with the exception of Female No. 2520 in the 50 mg/kg bw/day group. - Mortality:
- no mortality observed
- Description (incidence):
- All females in the control, 50, 150, and 600 mg/kg bw/day groups survived to the scheduled necropsy on Gestation Day 21.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- A lower (8.1%) mean body weight gain was noted in 600 mg/kg bw/day group when the overall treatment period (Gestation Days 6–21) was evaluated. Although mean absolute body weights in this group were comparable to the control group throughout the treatment period, a statistically significantly lower corrected body weight (5.4%) and corrected body weight gain (24.2%) were noted in this group. The body weight effects noted in the 600 mg/kg bw/day group were considered test substance-related and adverse.
Mean maternal body weights, body weight gains, corrected body weights, and corrected body weight gains in the 50 and 150 mg/kg bw/day groups, and mean gravid uterine weights at all dosage levels were unaffected by test substance administration. Differences from the control group were slight and not statistically significant. - Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- Mean maternal food consumption, evaluated as g/animal/day, in the 50, 150, and 600 mg/kg bw/day groups was unaffected by test substance administration.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- Test substance-related higher mean kidney weights (5-7%) were noted in the 50, 150, and 600 mg/kg bw/day groups; higher liver weights (4-7%) were also noted in the 150 and 600 mg/kg bw/day groups. Kidney and liver were not evaluated microscopically, but weight elevations were similar to those noted in the previous 28-day repeat dose study using the same dosage levels. There were no other test substance-related effects on organ weights.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- There were no observations that were considered to be associated with administration of the test substance at dosage levels of 50, 150, and 600 mg/kg/day
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- There were no test substance-related histologic changes.
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- no effects observed
- Description (incidence and severity):
- Thyroid hormones: In the 150 and 600 mg/kg bw/day groups, statistically significantly higher (72.7% and 69.7%,respectively) mean TSH concentrations were noted compared to the control group. In addition, a statistically significantly lower (30.0%) mean T3 concentration was noted in the 600 mg/kg bw/day group compared to the control group. Given the lack of any effects on thyroid gland weight at any dosage level or histopathology in the 600 mg/kg bw/day group, the differences in T3 and TSH hormones were considered test substance-related but nonadverse. There were no effects on T4 concentrations at any dosage level. In the 150 mg/kg bw/day group, a statistically significantly higher (18.0%) T4 concentration was noted compared to the control group; however, the difference in T4 concentration was not observed in a dose-dependent manner.
Maternal developmental toxicity
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- no effects observed
- Description (incidence and severity):
- Mean numbers of corpora lutea and implantation sites and the mean litter proportions of pre-implantation loss were similar across all groups.
- Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Description (incidence and severity):
- Intrauterine survival in all dose levels was unaffected by test substance administration.
- Changes in pregnancy duration:
- no effects observed
- Changes in number of pregnant:
- no effects observed
Effect levels (maternal animals)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 150 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- body weight and weight gain
Maternal abnormalities
- Abnormalities:
- effects observed, treatment-related
- Localisation:
- other: body weight gain
Results (fetuses)
- Fetal body weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- In the 600 mg/kg bw/day group, mean male (5.66 g), female (5.33 g), and combined (5.48 g) fetal weights were statistically significantly lower (5.39% to 5.84%) than the concurrent control group values (5.98, 5.66, and 5.81 g, respectively) and the historocal control data (5.955, 5.653, and 5.817 g, respectively). The effects on intrauterine growth at 600 mg/kg bw/day were considered test substance-related and adverse. Intrauterine growth was unaffected by test substance administration at dose levels of 50 and 150 mg/kg bw/day. The effects on fetal weight occurred together with maternal toxicity effects, but not as a secondary non-specific consequence of maternal toxicity effects.
- Reduction in number of live offspring:
- not examined
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- no effects observed
- Changes in postnatal survival:
- not examined
- External malformations:
- no effects observed
- Description (incidence and severity):
- No external malformations or developmental variations were observed in fetuses in this study.
- Skeletal malformations:
- no effects observed
- Description (incidence and severity):
- No test substance-related skeletal malformations were observed in fetuses in this study. Fetus No. 2523-03 in the 50 mg/kg bw/day group was noted with an absent lumbar vertebra. In the absence of malformations in the higher dosage levels, this malformation in a single low-dose fetus was not considered test substance-related.
- Visceral malformations:
- no effects observed
- Description (incidence and severity):
- No visceral malformations were observed in fetuses in this study.
- Other effects:
- no effects observed
- Description (incidence and severity):
- Mean absolute and relative (to the cube root of fetal body weight) anogenital distances in the 50, 150, and 600 mg/kg bw/day groups were comparable to the control group values. Differences from the control group were slight and not statistically significant.
Effect levels (fetuses)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 150 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- fetal/pup body weight changes
Fetal abnormalities
- Abnormalities:
- effects observed, treatment-related
- Localisation:
- other: body weight
- Description (incidence and severity):
- The effects on fetal weight occurred together with maternal toxicity effects, but not as a secondary non-specific consequence of maternal toxicity effects.
Overall developmental toxicity
- Developmental effects observed:
- yes
- Lowest effective dose / conc.:
- 150 mg/kg bw/day (actual dose received)
- Treatment related:
- yes
- Relation to maternal toxicity:
- developmental effects occurring together with maternal toxicity effects, but not as a secondary non-specific consequence of maternal toxicity effects
- Dose response relationship:
- yes
- Relevant for humans:
- not specified
Any other information on results incl. tables
See attachments for result tables.
Applicant's summary and conclusion
- Conclusions:
- In the prenatal developmental toxicity study, conducted according to OECD Test Guideline 414 and in compliance with GLP, the NOAEL for maternal and developmental toxicity was 150 mg/kg bw/day based on lower maternal body weight gain and lower fetal body weights at 600 mg/kg bw/day. The effects on fetal weight occurred together with maternal toxicity effects, but were not considered to be secondary non-specific consequence of maternal toxicity effects.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.